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PATHOGENESIS
Low Postseroconversion CD4 Count and Rapid
Decrease of CD4 Density Identify HIVþ Fast Progressors
Annette Audige´,1 Patrick Taffe´,2 Martin Rickenbach,2 Manuel Battegay,3 Pietro Vernazza,4 David Nadal,5
Roberto F. Speck,1 and the Swiss HIV Cohort Study (SHCS)
Abstract
CD4 expression in HIV replication is paradoxical: HIV entry requires high cell-surface CD4 densities, but
replication requires CD4 down-modulation. However, is CD4 density in HIVþ patients affected over time? Do
changes in CD4 density correlate with disease progression? Here, we examined the role of CD4 density for
HIV disease progression by longitudinally quantifying CD4 densities on CD4þ T cells and monocytes of ART-
naive HIVþ patients with different disease progression rates. This was a retrospective study. We defined three
groups of HIVþ patients by their rate of CD4þ T cell loss, calculated by the time between infection and
reaching a CD4 level of 200 cells/ml: fast (<7.5 years), intermediate (7.5–12 years), and slow progressors (>12
years). Mathematical modeling permitted us to determine the maximum CD4þ T cell count after HIV sero-
conversion (defined as ‘‘postseroconversion CD4 count’’) and longitudinal profiles of CD4 count and density.
CD4 densities were quantified on CD4þ T cells and monocytes from these patients and from healthy indi-
viduals by flow cytometry. Fast progressors had significantly lower postseroconversion CD4 counts than other
progressors. CD4 density on T cells was lower in HIVþ patients than in healthy individuals and decreased
more rapidly in fast than in slow progressors. Antiretroviral therapy (ART) did not normalize CD4 density.
Thus, postseroconversion CD4 counts define individual HIV disease progression rates that may help to
identify patients who might benefit most from early ART. Early discrimination of slow and fast progressors
suggests that critical events during primary infection define long-term outcome. A more rapid CD4 density
decrease in fast progressors might contribute to progressive functional impairments of the immune response in
advanced HIV infection. The lack of an effect of ART on CD4 density implies a persistent dysfunctional
immune response by uncontrolled HIV infection.
Introduction
Along with a chemokine receptor, CD4 forms the re-ceptor complex through which HIV enters a target cell.
The efficiency of viral entry and, thus, of the infection process
itself strongly depends on the level of expression of CD4 on
the surface of the target cell.1–5 Low levels of CD4 on cells,
such as macrophages, may be a significant barrier to entry by
certain HIV clones.6 In primary rhesus monkey macrophages,
a low CD4 density inhibits infection by SIVmac239 and R5
HIV strains. This impediment can be overcome by CD4
overexpression.7 In agreement with these observations, the
ability of the synthetic macrocycle cyclotriazadisulfonamide
to specifically down-modulate CD4 correlates with its anti-
HIV activity in vitro.8–10
On the other hand, in vitro and in vivo studies with SCID-hu
Thy/liv mice demonstrated the importance of CD4 down-
modulation for HIV replication efficiency.11–14 Furthermore,
Nef alleles from HIV strains isolated from patients with pro-
gression to AIDS efficiently down-regulate CD4, whereas
Nef alleles from HIV strains isolated from long-term non-
progressors are ineffective in down-modulating CD4.15–18
The well-known CD4 down-regulation by HIV in vitro is
mediated by the viral proteins Nef, Env, and Vpu.19 Several
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explanations have been proposed for why CD4 down-
modulation favors HIV, including attenuation of CD4 sig-
naling that might decrease viral transcription, prevention of
superinfection, and enhancement of virion release.19
Thus, the role of CD4 expression in HIV infection appears
paradoxical. Efficient entry of HIV into cells requires high cell-
surface densities of CD4, but CD4 down-modulation by HIV
gene productsmay be necessary for an effectiveHIV infection.
Few studies have examined CD4 expression in HIV-
infected individuals, and those have yielded conflicting
results. CD4 expression on peripheral blood T cells was sig-
nificantly lower in HIV-infected individuals than in HIV-
negative individuals.20,21 Patients with late-stage HIV disease
(as defined by<200 CD4þ T cells/ml) have significantly lower
T cell CD4 expression levels than patients in the early stages.20
In contrast, lymphocyte CD4 cell-surface densities have been
reported as constant throughout the disease.22
Thus, the role of CD4 expression levels for HIV pathogen-
esis remains unclear. Furthermore, previous cross-sectional
studies did not examine several key issues. Is CD4 density on
HIV target cells affected in HIVþ patients over time? If the
CD4 density changes, does it correlate with disease pro-
gression? Does suppression of HIV RNA copy number by
antiretroviral therapy (ART) affect CD4 density? To address
these questions, we defined three groups of HIV disease
progressors (i.e., fast, intermediate, and slow progressors),
according to the rapidness of their CD4 count decline (i.e., the
projected time from infection until the CD4 count reaches the
level of 200 cells/ml, calculated by a Bayesian mathematical
model23). CD4 densities were quantified on CD4þ T cells
and monocytes from these patients by flow cytometry.
We calculated the maximum CD4þ T cell count level after
seroconversion as described,23 which was defined as ‘‘post-
seroconversion CD4 count.’’ This method was also used to
determine the longitudinal profiles of CD4 counts and den-
sities. Finally, CD4 densities onHIV target cellswere analyzed
before and after the start of ART to determine the role of ART
on CD4 density.
Materials and Methods
Patients and cells
CD4þ T cell counts and viral load data were provided by
the data center of the Swiss HIV Cohort Study (SHCS). To be
included in the study, HIVþ patients from the SHCS had to
meet the following criteria. (1) Patients had to be starting their
first-line ART, during which (2) viremia had to be suppressed
to undetectable levels within 6–9 months and remain unde-
tectable for at least 6 months and (3) CD4 T cell counts had to
recover to 300 cells/ml within 6–9 months after the intro-
duction of ART. (4) At least three cryopreserved peripheral
blood mononuclear cell (PBMC) samples with 6106 cells
each had to be available from before the introduction of ART,
and one sample had to have undetectable HIV levels under
ART.
A Bayesian mathematical model was used to estimate the
unknown date of infection for each individual based on the
CD4 count measurements and the seroconversion window
defined by the last negative and first positive documented
HIV tests.23 Using 405 patients with 3 blood samples stored
before the initiation of ART and for whom a date of infection
could be estimated, three groups of patients were defined,
according to the estimated time from seroconversion to the
date when CD4þ T cell counts decreased to 200 cells/ml. These
were rated as fast, intermediate, and slow progressors for
patients with less than 7.5 years, 7.5–12 years, and >12 years,
respectively. The cut points represent tertiles (i.e., n¼ 135, 134,
and 136, respectively). Mathematical modeling permitted us
to approximate the maximum CD4þ T cell count level after
seroconversion, defined as ‘‘postseroconversion CD4 count,’’
the longitudinal profiles of CD4þ T cell count, and viral load.
To analyze the time profiles of the CD4 T cell andHIV RNA
markers, particularly near the time point of infection, 516 in-
cident cases were selected from the SHCS. For these patients,
the date of infection is known with good precision as they
were seen by a clinician during primary infection or had a
negative and positive test for HIV infection within a conve-
niently narrow time interval (here<1 year). In those cases, the
date of infection was estimated as the mid-point.23 These
patients are well known to be different from prevalent cases.
They are, however, very useful for assessing the trajectories of
themarkers from our three groups of progressors (whichwere
defined on prevalent cases), as they provide many measure-
ments during the first few year after the infection occurred
(whereas prevalent cases usually provide measurements only
at a later stage of disease).
Of the 405 patients having 3 blood samples stored before
the initiation of ART and for whom a date of infection could
be estimated, 21, 20, and 17 fast, intermediate, and slow
progressors, respectively, were selected based on the above-
mentioned criteria for fluorescence-activated cell sorting
(FACS) analyses. Of these, 13, 15, and 12 fast, intermediate,
and slow progressors, respectively, passed the criteria for cell
viability by FACS analysis (see below). As controls, PBMCs
from 10 healthy HIV-negative individuals were isolated at
two different time points (5 to 12 months apart) and cryo-
preserved for 14 days (range: 14 days to 11 months).
Immunostaining and flow cytometry
Cryopreserved PBMCs were rapidly thawed and recov-
ered in RPMI medium containing 10% fetal calf serum (FCS).
CD4 cell-surface expression levels on CD4þ T cells and
monocytes were quantified indirectly with the QIFIKIT
(DakoCytomation), which allows the antigen quantity to be
expressed in specific antibody-binding capacity (SABC)
units. Cells were first incubated with unconjugated primary
monoclonal antibody against CD4 (clone RPA-T4) at a sat-
urating concentration or the corresponding isotype antibody
in phosphate-buffered saline (PBS), 0.1% bovine serum
albumin (BSA), and 0.1% sodium azide (PBS-BSA-azide) at
48C for 30min (all antibodies used in this study were from
BD Biosciences Pharmingen). Cells, set-up beads, and cali-
bration beads were washed with PBS-BSA-azide and incu-
bated with FITC conjugate, according to the manufacturer’s
instructions at 48C for 30min. Cells and beads were washed
with PBS-BSA-azide. Beads were resuspended in PBS-BSA-
azide and kept at 48C until flow cytometric analysis. Cells
were then incubated with mIgG (Sigma; end concentration,
5 mg/ml) at 48C for 10min, centrifuged, and incubated with
anti-CD3 PE and -CD14 APC antibodies at 48C for 20min.
The rationale for preincubating the cells with mIgG was a
strong unspecific binding of the anti-CD14 APC monoclonal
antibody to CD4-FITC conjugate-stained cells, which could
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be prevented by preincubation with mIgG (data not shown).
Cells were washed with PBS-BSA-azide, resuspended in
PBS-BSA-azide, and immediately acquired on a FACSCali-
bur (BD Biosciences).
Data were analyzed with FlowJo software (Tree Star).
Lymphocytes were defined based on the forward-scatter
(FSC) and side-scatter (SSC) properties and their CD3þCD14
phenotype, whereas monocytes were defined by their FSC
and SSC properties and CD3CD14þ phenotype. A total of
20,000 beads and 10,000 live cells (lymphocyte and monocyte
gates combined) were acquired. Antigen density was calcu-
lated according to the manufacturer’s instructions.
Data were excluded from statistical analyses if the per-
centage of cells in the lymphocyte gate (as defined by the
FSC/SSC profile) was<20% or if the percentage of cells in the
monocyte gate (based on the FSC/SSC properties) was <5%.
Statistics
The postseroconversion profiles of CD4 count (on the
square root scale), viral load (on the log to base 10), and CD4
density (on the untransformed scale) were linear over time
and were completely determined by the intercepts and slopes
for each group of progressors.
The profiles were compared among the three progressor
groups with marginal and mixed longitudinal linear
models.24 In the context of linear models, the main difference
between the two models resides in the assumptions of con-
stancy of the variance and stationarity.25 When the variance
was approximately constant (on the chosen scale), a stationary
marginal model with autoregressive of order 1 errors was
used. When it was increasing with time, a mixed model (with
random intercept and slope) was considered.
The bivariate relationship between the levels of CD4 count
and receptor density was studied using linear mixed models,
to account for repeated measurements per individual. Binary
indicators (0/1) variables were used to define an intercept and
slope for each group of progressors, and these parameters
were compared using Wald tests.
Statistical analysis was performed with STATA 10 (STA-
TACorp, College Station, TX). The level of significancewas set
at p< 0.05.
Results
Fast progressors have a significantly lower
postseroconversion CD4 count level than
slow progressors
The postseroconversion longitudinal profiles of CD4 count
and viral load were analyzed for the three HIVþ patient
groups (i.e., fast, intermediate, and slow progressors). The
three groups of progressors were characterized by different
CD4þ T cell count intercepts (or ‘‘postseroconversion CD4
counts’’)23 and slopes (slopes: p¼ 0.016, intercepts: p< 0.001,
slopes and intercepts: p< 0.001) (Fig. 1A). Themain difference
between intermediate and fast progressors was the lower
CD4þ T cell count intercept for the latter. Slow progressors
had the same CD4þ T cell count intercept as intermediate
progressors, but the slope was less steep. This phenomenon is
even better illustrated with the CD4 count profiles of the three
patient groups in 516 incident cases (Fig. 1B). Thus, fast pro-
gressors are distinguished from slow progressors by a more
rapid decrease of CD4þ T cells over time and a significantly
lower postseroconversion CD4 count level.
In all three groups of progressors, viral load (log to base
10) increased over time (Supplemental Fig. 1; see www
.liebertonline.com/aid). The RNA set point was higher for fast
progressors, whereas the difference between intermediate
and slow progressors was less pronounced. RNA slopes were
somewhat less steep for slow progressors than for fast and
intermediate progressors (slopes: p¼ 0.756, intercepts:
p¼ 0.604, slopes and intercepts: p< 0.001).
ART does not restore CD4 densities on CD4þ
T cells to physiological levels
CD4 densities on CD4þ T cells and monocytes were com-
pared at the three time points before ART and after ART of all
HIVþ patients and between HIVþ patients and HIV donors.
CD4 densities were significantly lower on CD4þ T cells (Fig. 2)
but not monocytes (data not shown) of HIVþ patients at any
time before or after ART than on those of HIV-negative vol-
unteers ( p< 0.001). CD4 densities on CD4þ T cells (Fig. 2) and
monocytes (data not shown) fromHIVþ patients were similar
before and after ART ( p¼ 0.12).
CD4 densities decrease more rapidly in fast
than in slow progressors
CD4 densities on CD4þ T cells and monocytes were ex-
amined longitudinally (before ART) for the three patient
groups. CD4 densities on CD4þ T cells decreased over time in
all three groups of progressors, but with a different course: the
decline was more rapid in fast and intermediate progressors
than in slow progressors; the intercepts were similar for fast
and intermediate progressors, but somewhat lower for slow
progressors (slopes: p¼ 0.108, intercepts: p¼ 0.528, slopes and
intercepts: p¼ 0.051) (Fig. 3). In contrast, CD4 density longi-
tudinal profiles of monocytes showed no clear differences
among the groups (data not shown).
CD4 counts and CD4 densities are related
essentially in slow progressors
The bivariate relationships between CD4 count and CD4
density on CD4þ T cells of HIVþ patients were examined in
the three progressor groups by linear mixed models to ac-
count for repeated measurements per individual. The rela-
tionships were significantly different among the three groups
of progressors, with the slope being the main difference
(slopes: p¼ 0.312, intercepts: p¼ 0.921, slopes and intercepts:
p¼ 0.014) (Fig. 4). CD4 count and CD4 density were signifi-
cantly correlated only in the case of slow progressors
( p¼ 0.0279).
Discussion
To dissect the role of CD4 density in HIV pathogenesis, we
longitudinally quantified the CD4 densities on CD4þ T cells
and monocytes of ART-naive HIV-infected patients with
different disease progression rates. A newly developed
mathematical model integrating the CD4þ T cell loss over
time, as well as information on the last negative and first
positive documented HIV tests, permitted us to determine the
‘‘postseroconversion CD4 counts’’ and the longitudinal CD4
density profiles and compare these parameters between the
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FIG. 1. CD4þ T cell counts of HIVþ patients over time. Shown are the square roots of CD4þ T cell counts over time (in years
of infection) for the three patient groups in the 40 patients evaluated (n¼ 13, 15, and 12 for fast, intermediate, and slow
progressors, respectively) (A) and in 516 incident cases (n¼ 332, 78, and 106 for fast, intermediate, and slow progressors,
respectively) (B). Global Wald tests of equality of slope and intercept were performed by modeling the longitudinal profiles.
Marginal and mixed longitudinal models were used. (Color image can be found at www.liebertonline.com/aid).
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three different progressors groups. Our main findings are
that (1) fast progressors had a lower postseroconversion
maximum CD4 count level than intermediate and slow pro-
gressors, (2) CD4 density on CD4þ T cells, but not on mono-
cytes, was significantly lower at any time point in HIVþ
patients than in HIV individuals, (3) CD4 density on CD4þ T
cells decreased more rapidly in fast than in slow progressors,
(4) the relationship betweenCD4 T cell count andCD4 density
on CD4þ T cells and monocytes over time was significantly
different between the three groups of progressors, and (5)
fully suppressive ART did not restore CD4 density on CD4þ T
cells from HIVþ patients to levels found in healthy donors.
Our analysis of the postseroconversion CD4 count profiles of
the three patient groups over time led to an intriguing finding.
Fast progressors were differentiated from slow progressors not
only by a more rapid decline of their CD4þ T cell counts, but
also by a lower maximum CD4 count level attained after sero-
conversion. Intermediate progressors were distinguished
from fast progressors by a higher postseroconversion CD4
count level and from slow progressors by a steeper CD4þ T
cell count slope. Thus, fast progressors appear to recover
CD4þ T cells less efficiently than intermediate and slow pro-
gressors after primary infection and, in addition, lose them
more rapidly thereafter than slow progressors. These data
also imply that pathogenic events in primary HIV infection
may prime the long-term outcome of HIV disease.
The postseroconversion longitudinal profiles of viral load
were also different between the three progressor groups.
However, this difference, even though significant, was not as
clear as that in the CD4 count profiles over time. Thus, in our
study, viral load set point and/or slopewere less discriminating
factors among the three progressor groups than the post-
seroconversion CD4 counts.
Notably, more than 10 years ago, seminal work estab-
lished levels of HIV RNA copy numbers at about 6 months
postinfection that predict individual risk of progression rate.
This was defined as the viral set point.26,27 More recently, an
immunological set point early in HIV infection was estab-
lished to determine the risk of CD4þ T cell decline.28 Our
data suggest that in addition to the level of viremia and
extent of immune activation in early infection, the maximal
level of CD4 count attained after seroconversion may have
prognostic value for guiding therapy. Two recent studies
showed that initiating treatment during acute HIV infection
improves the CD4þ T cell count.29,30 Thus, patients with a
high viral load set point, as well as patients with a low
postseroconversion level of CD4 count, are likely to benefit
from early treatment.
The CD4 density on CD4þ T cells was significantly lower in
HIVþ patients at any given time point before or after ART
than in healthy individuals. Two previous cross-sectional
studies also found CD4 expression on peripheral blood T cells
to be significantly lower in HIV-infected than in HIV-negative
individuals.20,21 In our study, the mean CD4 density on CD4þ
T cells from healthy individuals was lower than that reported
in the literature.20,21,31 This discrepancy is most likely ex-
plained by the different methods employed: we used indirect
immunostaining to quantify the number of SABC units as an
estimate of CD4 density, whereas the previous studies used
direct immunostaining. Of note, the interindividual variation
was within the range of that observed in the previous studies.
Surprisingly, successful suppression of HIV viremia by ART
did not restore CD4 expression to physiological levels. In fact,
ART had no effect on CD4 density. Lack of or only partial
restoration is a well-known phenomenon in HIV disease
subsequent to ART (e.g., incomplete recovery of CD4þ T
cells32,33 or normalization of immune activation28). We cannot
exclude a protracted clearance of HIV gene products that are
known to down-regulate CD4 expression, such as Nef, Env,
and Vpu,19 while HIV RNA is already suppressed. Thus,
FIG. 2. CD4 density on
CD4þ T cells of HIVþ patients
before and after ART and of
HIV donors. CD4 densities
on CD4þ T cells (in SABC
units) were compared at the
three times before ART (BH1,
BH2, BH3) and after ART
(AH) of all HIVþ patients
(n¼ 40 for each time point) as
well as between HIVþ patients
and HIV donors (n¼ 10). For
each HIV donor, the mean of
CD4 density at two different
times was used. Whiskers of
boxes represent upper and
lower boundaries defining
extreme values. Data were
analyzed using the Wilcoxon
Mann–Whitney rank-sum test.
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analysis of CD4 expression levels at later time points might
show partial or even complete recovery. Also of note, CD4
down-modulation occurred on the entire CD4þ T cell popu-
lation, although only very few cells are infected in the chronic
phase of HIV infection.34–37 Thus, indirect factors seem to be
responsible for the CD4 down-modulation in HIVþ patients.
One element that may result in CD4 down-modulation could
be a dysfunctional cytokine network. Indeed, acute HIV in-
fection is associated with an intense early cytokine ‘‘storm’’ in
contrast to more moderate and delayed cytokine responses
in acute hepatitis C virus or hepatitis B virus infections.38
Alternatively, soluble HIV proteins, such as Nef, Vpu, or Env,
may contribute to the effects observed.19
The decrease of the CD4 density of CD4þ T cells over time
tended to be more rapid in fast than in slow progressors.
Notably, the more rapid decline of CD4 density in fast and
intermediate progressors occurred despite their slightly
higher baseline level of CD4 expression as compared to slow
progressors. Similarly, Ginaldi et al. reported significantly
lower CD4 expression levels on T cells in patients with late-
stage disease (i.e., patients with<200 CD4þ T cells/ml) than in
those with early stage disease in their cross-sectional study.20
In contrast, Poncelet et al. found no difference in lymphocyte
CD4 density between HIV-infected patients and healthy
volunteers and consequently also no dependency on disease
stage.22 This discrepancy is likely explained by differences in
the methods employed. Finally, data from in vitro studies also
show an association of CD4 down-modulation with disease
progression: Nef alleles from HIV strains isolated from
patients with progression to AIDS efficiently down-regulate
CD4, whereas Nef alleles fromHIV strains isolated from long-
term nonprogressors are compromised in their ability to
down-modulate CD4.15–18
Importantly, the progressive CD4 down-modulation on
CD4þ T cells in HIVþ patients may contribute to the func-
tional impairment of CD4þ T cells observed in HIV in-
fection.39 CD4 plays an essential role in the generation of
adaptive immune responses by acting as a coreceptor with the
T cell receptor/CD3 complex, which binds peptide-MHC
complexes. Furthermore, CD4 acts as a binding receptor for
interleukin (IL)-1640; ligation of IL-16 by CD4 may switch
CD4þ T cell function from immune to inflammatory func-
tions.41 Both functions may be affected by the reduced ex-
pression levels of CD4 in HIVþ patients.
CD4 down-regulation by memory CD4þ T cells was re-
cently proposed as a key mechanism by which African green
monkeys survive SIVagm infection without developing
AIDS.42 These data might contrast with our findings of
increased CD4 down-regulation in progressive HIV disease.
However, they might also indicate that CD4-downregulation
is not the pathway leading to CD4 depletion. The dis-
crepancies between the studies emphasize that data obtained
in monkeys must be interpreted with caution and must be
corroborated in primary samples from human.
We also examined the bivariate relationship between CD4
count and CD4 density on CD4þ T cells of HIVþ patients and
found that the two parameters were related only in slow
progressors. Thus, the dynamics of CD4 T cell decline and
decrease of CD4 density on CD4þ T cells are similar in slow,
but not in intermediate and fast progressors. We may spec-
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FIG. 3. CD4 density on CD4þ T cells of HIVþ patients over time. Shown is the CD4 density on CD4þ T cells in SABC units
over time (in years of infection) for the three patient groups. Tests were performed as described in Fig. 1. (Color image can be
found at www.liebertonline.com/aid).
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ulate that host factors, such as the cytokine network, are
dysfunctional to different degrees in the three progressor
groups, affecting the relationship between CD4 count and
CD4 density on CD4þ T cells.
We also quantified CD4 densities on monocytes of HIVþ
and HIV individuals. Monocytes are precursors of dendritic
cells and macrophages, which are among the first targets in
sexual HIV transmission and thus are key components in HIV
pathogenesis.43 In line with published data,31 physiological
levels of CD4 density on monocytes (i.e., those found in
healthy persons) were approximately one-third those on
CD4þ T cells (data not shown). In contrast to CD4þ T cells,
CD4 densities on monocytes were not lower in HIVþ patients
than in healthy individuals (data not shown). Furthermore,
over time, CD4 density profiles of monocytes from the three
patient groups were similar. Thus, CD4 cell-surface expres-
sion is regulated physiologically and modulated by HIV in a
cell type-specific manner.
Despite the clear-cut results of the statistical analyses, our
conclusions as related to the CD4 densities are limited by
the small number of patients analyzed. Thus, we consider
this as an intriguing tendency that is more exploratory than
conclusive and one that should be confirmed in a larger cohort.
In summary, this study clearly demonstrates that the CD4þ
T cell count early in infection determines an individual’s HIV
progression rate. Thus, the postseroconversion CD4 count
adds to the viral or immunological set point as a prognostic
factor in early HIV infection. The prognostic implication of a
lower postseroconversion CD4 count level also indicates that
critical events during primary HIV infection prime the long-
term outcome of HIV disease. Furthermore, this work reveals
that rapid down-modulation of CD4 is associated with rapid
disease progression that may contribute to the progressive
functional impairment of the immune system, which may
even persist after successful suppression ofHIVRNAbyART.
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FIG. 4. CD4 count versus CD4 density on CD4þ T cells of HIVþ patients. The bivariate relationship between CD4 count (in
square root) and CD4 density (in SABC units) on CD4þ T cells was studied for the three patient groups with linear mixed
models to account for repeated measurements per individual. (Color image can be found at www.liebertonline.com/aid).
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